RMC-5127 — FDA meeting
H2 2026
The company remains on track to identify a recommended monotherapy Phase 2 dose for this compound in the second half of 2026.Source filing
RVMD biotech catalysts & pipeline
REVOLUTION MEDICINES INC · Data as of 2026-10-25
Upcoming catalysts
RASONQUE™ (daraxonrasib) — Initial data
2027
Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.Source filing
RMC-5127 — Initial data
2027
The company remains on track to identify a recommended Phase 2 dose during the second half of 2026 and expects to share initial clinical data in 2027.Source filing
zoldonrasib — Conference presentation
2026
The company plans to share initial clinical data evaluating the combinations of zoldonrasib plus gemcitabineSource filing